NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Press Release
Read More
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system
Literature
Read More
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Press Release
Read More
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Press Release
Read More
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Press Release
Read More